Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 408
Selected: 0
NCT IDTitle
NCT03890068Anlotinib Maintenance Treatment for Advanced Soft Tissue Sarcoma
NCT03996408Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Cholangiocarcinoma
NCT05400876To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory Lymphoma
NCT05011019A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis
NCT05487976Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With Inhibitor
NCT05745363Clinical Study of AL2846 Capsule in the Treatment of Differentiated Thyroid Cancer
NCT07172126Clinical Trial to Evaluate the Tolerance of TQB3201 Tablets
NCT04056572Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
NCT04340427A Study of TQB3455 Tablets in Subjects With Advanced Malignancies
NCT06413953A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors
NCT02809534A Study of Anlotinib in Patients With Hepatocellular Carcinoma
NCT04405505A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)
NCT05020639A Study of TQB3820 in Patients With Hematological Malignancies
NCT04619537A Trial of Anlotinib Combined With Docetaxel in Patients With Wild-type Advanced Non-squamous Non Small Cell Lung Cancer
NCT04956328Study of Obeticholic Acid(OCA) Combination With Ursodeoxycholic Acid (UDCA) in Patients With Primay Biliary Cirrhosis (PBC)
NCT06106841TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
NCT03897283Study of TQB2450 Combined With Anlotinib in Patients With Advanced Solid Tumors
NCT05775575A Clinical Trial of TQB3909 Tablets in Patients With Breast Cancer
NCT06931145Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
NCT06452706The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
NCT07008976Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer
NCT06251947Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen
NCT03790228Anlotinib Combined With Pemetrexed And Carboplatin as First-line Treatment in Advanced Nonsquamous NSCLC
NCT02622932Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients
NCT06829771Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
NCT07107256Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps
NCT06388759TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients
NCT05340530To Evaluate the Pharmacokinetic Effects of TQD3606 for Injection in Healthy Adult Subjects
NCT05870436A Study on the Diagnostic Value of the Methacholine Choline Provocation Test in the Asthmatic Population
NCT05894421TQB2223 Injection in Combination With Penpulimab in Patients With Advanced Cancers
NCT05472324Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Severe Asthma.
NCT06585059Clinical Trial of TQB2928 in Combination With a Third-Generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients With Advanced Non-Small Cell Lung Cancers
NCT06326671A Trial to Assess the Bioequivalence of Generic Tiotropium Bromide Inhalation Powder and Reference Product in Healthy Adult Participants Under Fasting Conditions (Pilot)
NCT06085053A Clinical Trial of TQA3038 Injection in Healthy Adult Subjects
NCT05198505Clinical Trial of TQB2868 Injection in Subjects With Advanced Malignant Tumors
NCT06431490A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
NCT04002622Study of TQB2450 Injection in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma
NCT05675202Material Balance Study of TQ-B3525
NCT05563480TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
NCT06415903A Clinical Trial of TQB3117 Tablets in Patients With Advanced Malignant Cancer
NCT03527888Study of Anlotinib in Patients With Primary Malignant Bone Tumors
NCT02779699A Study of AL2846 on Tolerance and Pharmacokinetics
NCT03750916Anlotinib Combined With Docetaxel for Advanced Non-squamous Non-Small Cell Lung Cancer
NCT02029209To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer
NCT04012619Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung Cancer
NCT06682169Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease
NCT06854445Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
NCT01940731Efficacy and Safety of Colistimethate Sodium Injection Vial to Treat Hospital-acquired Pneumonia in Adults
NCT05718167TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.
NCT04412577A Study of TQB3473 Tablets in Subjects With Relapsed or Refractory Hematological Malignancies